Reddit Posts
Swing trade ideas! Some are good, some are risky and some are degen!
$AQST - Long-term high-risk, high-reward, pharma play w/ potential for +1000% return
$AQST - Long-term high-risk, high-reward, pharma play w/ potential for +1000% return
AQST Huge Potential. Mods if you delete this you’re missing a chance of a lifetime
$SURF, $OLB, $CGEN, $AQST, $LTCH, $JUPW--Hello $1.00 Land
Knocking on the $1.00 Door-- $SURF, $OLB, $CGEN, $AQST, $LTCH, $JUPW
$AQST - Long-term high-risk, high-reward, pharma play w/ potential for +1000% return
Global Warming Solutions Progresses On Business Plan. Provides Battery Testing Update
Global Warming Solutions, Inc. Shareholder Update on 2-in-1 Sodium Battery and Hydrogen Generator System Development
[DD] $AQST - Libervant - A New Non-invasive and Innovative Treatment for Seizures
AQST. Anyone still looking at this??? 🤔
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)
Point on PTPI, AQST & ARDX the hard way, Ladies and Gentlemen: good luck with your plays this week. The casino is open 🎲🎲
$AQST Aquestive Therapeutics has imminent FDA news due and with an analyst price target of around $15 this stock could be primed for a squeeze.
$AQST The FDA decision is imminent and the expected positive news could lead to a huge squeeze.
AQST Stock: What Will Happen If The FDA Approves Libervant? AQST Stock F...
HUGE AQST PROFIT POTENTIAL. Found this winner just browsing tickers. The new drug coming out in DEC…….. wait for it….. SUBOXONE!
This Penny Stock AQST has a major CATALYST and is set to make HUGE GAINS🚀📈
Aquestive Therapeutics PDUFA Dec 23, 2021 Potential Runner
First Post on Aquestive Theraputics, why I think this has a lot of potential PDUFA Dec 23,2021
My First Post on Aquestive Theraputics on why I feel this stock can make a big run
Aquestive Therapeutics Inc. Game Changing Delivery System PDUFA Dec 23 POTENTIAL RUNNER
$AQST NEXT BIG RUNNER!!!! PDUFA DATE DECEMBER 23RD 2021
Aquestive Therapeutics Inc (AQST) Stock Forecast
AQST stock to buy? Low float, new product, great company
AQST weekly chart: Its finally crossed the Rubicon of almost year long downward resistance slope. PDUFA runup to Dec 23rd about to commence.
WALLSTREETBETS: Wednesday Rundown, Thursday Expectations - PMCB Stock, SGOC Stock, VRPX Stock, WTER Stock, AQST Stock, SOS Limited Stock, ENVB Stock UPDATE
Forgive me if I’m being naive so go gentle - why not meme AQST? I’m new to meme stocks and generally don’t touch them due to ridiculous margins on trading platforms.
Forgive me if I’m being naive so go gentle - why not meme AQST? Cheap.
Forgive me if I’m being naive so go gentle - why not meme AQST? Cheap
IntelGenx, Psilocybin, is a double from here, says Leede Jones Gable
Mentions
AQST - They received an FDA complete response, but the denial is based only on packaging issues. They will become the second needle-free replacement for Epi pens.
AQST gonna rip?
AQST popping up on news
AQST has news and a kinda high float which is why it's moving a bit slow
AQST up 20% off CRL announcement
Sold out of SWVL, made a decent profit, it looks like AQST had some news?
AQST announced receipt of a CRL for Anaphylm, FDA cited human factors (ease of opening packet + placement of film within packet) and have asked for supportive PK data to show that any adjustments to this won't impact efficacy.
Anyone been watching AQST? They dropped from around $6 to $3.50 on 9th Jan. when they disclosed FDA identified deficiencies on a form 483, and have slowly bled down to sub-$3 since then. Was thinking of getting in if it dips on delay or CRL news, top-line PK data looks really good despite FDA concerns and they have $120mil cash to last a year or so.
don’t miss the AQST short…FDA decision by tmrw
What do we think of AQST? FDA approval con Jan 31
DRCT and in particular SOBR are the top watch for me. Short trading weeks + good short stats + NASDAQ threshold list means that they should go at some point. Not bothering with news plays as even with great news (AQST) is having the opposite effect. Gold and gas plays are also in
AQST - Dumped 40% Friday. They yesterday announced letter from FDA stating that deficiencies had been identified in the NDA (PDUFA date Jan. 31) which prevented labeling discussions and post-marketing commitments. FDA did point out that NDA is still open and this was not a rejection letter. This could be something minor that AQST can supply resolving information or data for in time to keep the Jan. 31 PDUFA date. However, that date is only 3 weeks away and AQST stated that don't even know right know exactly what it is FDA needs. Seem unlikely that AQST will be able to figure out is needed and supply it in enough time for FDA review it prior to Jan. 31. At this point we don't know what FDAs'concern are. But even if they are minor, its not likely that 3 weeks is enough time to for AQST to address them and for FDA to review the submission addressing them. IMO - As of now, most likely outcome is that the Jan 31 PDUFA date will be delayed. This will surely result in another negative hit to the share price when the delay is announced. Also -it is a little concerning that just this Thursday AQST posted on their LinkedIn page that they are looking to hire a new quality control senior manager. Doh! Even if that posting has nothing to do with the FDA letter the timing of that post concurrent with the FDA letter has poor optics. Had considered that the dump Friday was an overreaction and thought about bottom-fishing on Monday. I will most likely not be bottom-fishing AQST early next week and will instead be keeping an eye out for more information and clarity on this FDA provided wrinkle.
There is a very real chance AQST doesn't get the labelling done by the 31st. It leaves them very little time to rush it through which makes AQST much more of a gamble than it might seem. This is pure coinflip gamble stuff, So personally, I'm staying out.
There is a chance AQST doesn't get the labelling done by the 31st which makes it not a sure thing but rather a coinflip whether they can get it done by then or not. So a coinflip for no CRL or a CRL. A gamble
I'm not following AQST and only know what you have posted and then a quick look at the chart just now. I see it dropped 40% today. Yes, if the only reason it dropped was labeling and marketing (and again, I'm just going off what you said) then that is a market overreaction. I'll look into it tomorrow morning and post here with my thoughts and of course, they are only my thoughts. not financial advice. If this really is an overreaction, I might pick up some shares or short-term call options. 😀
So, in essence, AQST only dropped because the FDA brought up concerns with labeling and marketing? Seems like quite the overreaction. Am I missing something?
If AQST breaks this $4 wall, it could regain a lot of ground before market open.
Hmmm. How much ground can AQST take back here? Hoping for a massive rebound. I bought near the floor. Major market overreaction to the news.
AQST might be a really good rebound play if it dumps again at open. News is bad but not lose 50% of market cap bad. It honestly might recover even before market open but I would wait for open to determine if you want to take a position or not.
AQST has just burned me hard. Such bad news weeks before the PDUFA date is not something that's happened to me before. I can't lie, this really stings.
Back from Christmas break after a bit of trading burnout. I've decided I will focus less on day-trading and quick 1-3 day swings and shift my focus back to 2-5 week swings. That being said, here are my call outs: AQST - target PDUFA date of 31 Jan for anaphylm. I'm expecting a run-up in price up to this date. I tend not to hold for the news, but I may do depending on price action. TVTX - target PDUFA date of 13 Jan for its FSGS drug. I'm not expecting much of a run-up as I may have jumped in a little late, but I don't see it going down before that date. I'm still undecided if I'll hold for news. Also in SQFT as others have called before me for a quick swing. Also in XBIT as there is supposed to be a data readout on 15 Jan but there is a potential issue with data so I may have to dispose of this before then but I'm keeping my eye on it.
AQST. Their oral film epinephrine is soon to be approved by the FDA next month
I wouldn’t yolo it at this point but AQST. I’m up like 30k off an investment of 20. They have a big drug approval planned for the 31st. If it’s rejected it will be a potentially great buying opportunity because dilution is almost guaranteed and the panic sell-off will be huge. If it is approved I expect it to surge to $10 or higher within the year. Do your DD though and don’t listen to me.
i will echo sofi, and give you AQST, pharmecuticals, they have a , for lack of a better word, epi film they are in stage 3 clinical trials with, just put it on your tongue and it dissolves, no injection, like the epi pen, not snorting it like the nasal spray, as a father with a son who has allergies, and forgets his pen or stops taking it with him, this is a game changer, they have a small pouch that will attach to a phone so it will always be there , kids always have their phones. Addressable market is huge. They also have some other drugs they are working on for Parkinson’s and seizures, worth a look at 6 bucks a share
$AQST Watching. My brother in law’s a doctor and he put me on this last night lol. Perks of having someone who’s a doctor in the family is that you basically get inside info on these pharma stocks.
You are also missing AQST for Anaphylm, sublingual epinephrine, stamp size, conservation within 18 minutes, compared to intramuscular injection of evidence, shelf stable expected approval with the FDA by 01/31/2026.
I like AQST for sure. I only own a couple hundred shares but I just bought options for February and May 2026 at six dollars strike price. They are waiting on FDA approval for a new drug that could be life-changing. They were just issued two new patents as well.
I got into CLNN a few months back, it’s waiting for FDA approval for its nanotechnology work to treat ALS, MS and Parkinson’s. SRRK and AQST are some other speculative plays I am in. SRRK is pending approval upon sorting a manufacturing issue
Should’ve picked AQST at least it has potential
Probably a bit late but AQST should cycle down over the next week or so and then begin climbing again in anticipation of a PDUFA date on a high rev potential drug. I would probably wait to accumulate in the 5-5.30 range. $7-8 pre pdufa seems likely.
The bear case that this doesn't work is bunk. SPRY just published real world clinical data on the effectiveness of Neffy and it is on-par with injectable Epi pen. I've spoken with multiple allergists who all confirm this works as well as the pen. The new bear point is that insurance isn't covering it and AQST's Anaphylm (oral strip Epi) will get approved and beat Neffy. 1) Insurance always drags their feet initially, good products get covered over time. 2) Even if Anaphylm is approved, I think Neffy and Ana split the market...how many people trust themselves to not lose their life saving device when it is the size of a band-aid (the oral strip)? Especially for kids and teens. I own a lot of SPRY and a little AQST, this is the first innovation in Epinephrine in a long time.
Solid DD, but remember FDA runs are pure binary - you either moon or crater overnight. $AQST has the faster TMax edge, but size your position like it could go to zero. Smartest play is scaling in/out instead of going full YOLO into Jan 31.
AQST - FDA target action date January 2026.
I'll play I've got 7 GOOG MO AMSC AQST ARQT JOBY QS not in any particular order
What’s going on with AQST? Thought PDUFA date is in Jan
AQST moving 2 days in a row!
Are any of you chucklefucks following AQST. The mouth breather allergic basement dwelling brother of yours is going to be buying their shit soon.
AQST had a good squirt today
LTRX and AQST. Both are rising.
If you’re game for biotechs with upcoming catalysts AQST could be interesting. Roughly 6 months out from FDA decision on anaphylm which is like a listerine strip version of EpiPen.
$AQST looking to revolutionize the pharma space with new distribution methods for life saving medicine
AQST . It has current market cap of 225Mil. It has 6 approved products and generates 50Mil revenue. Outstanding shares 99.33 Mil shares and 67Mil cash on hand. It submitted NDA for Anaphylm (an epinephrine anaphylaxis sublingual film) package on April, waiting for NDA acceptance in the next month, in 2-3 weeks. Which means pdufa regular 20 months i send of Jan or early Feb 2026. Global market size of Anaphylaxis epinephrine is set to be 4.5Bil by 2032. Even if Anaphylm, if approved , takes 5% of the pie, It would be the current MC.
dw i lost all my money on AQST
Honestly. This one has been on my watch list for a while now. Think there is potential. Always a good amount of risk with bio stocks (I am on ARDX and AQST… and watching MIST and AKBA also). May open up a position soon once I free up some funds from other plays. Good luck!
AQST looking ready to keep moving up. Might not be a BBAI pop but she'll move. Lots of institutional purchase and continued positive news/developments.
AQST popped a good bit with new price targets at $11! [Source](https://www.marketbeat.com/instant-alerts/analysts-set-aquestive-therapeutics-inc-nasdaqaqst-target-price-at-1100-2025-02-12/)
Sooo. Bullish on. AQST
You would be deeply wrong to be so optimistic. You should also see how the street is receiving cell therapies at the moment — see AUTL, ADAP, CABA, et al. Even after approval, they’re getting wrecked because CAR-T has been proven in a majority of cases (as in, over 75% of patients in some cases) to produce secondary lymphomas (yes, a cancer treatment with a 75% likelihood of giving you _another_ form of cancer), ICANS, cytokine storm, neurotoxicity, and all other kinds of nasty AEs. They are finding the T Cells themselves in these secondary lymphomas, meaning the cells themselves are directly causing these adverse events. The FDA is likely going to put warnings to this effect on _all_ CAR T therapies, which is making the likelihood of them becoming first line treatments (i.e the treatment you would use when first diagnosed) very low. If a treatment can only be used for second or third line treatment, it immediately only has access to ~20% of the market, virtually signing its death warrant as a blockbuster drug, and severely limiting upside. Not to mention, it’s in Ph1, which only really tests safety and tolerance, rather than efficacy, on a much smaller patient population, no less. You will be waiting for _years_ to see _any_ traction, and even then, by the time that traction arrives, CAR T therapies might well be out of vogue. It’s an incredibly risky (read: unlikely to work out) play and you’d be better investing in something like AQST which has Anaphylm, a replacement for the epi-pen that uses a sublingual film instead of an injector. They recently hired the woman responsible for turning the epi-pen into one of the most profitable drugs of all time, so they’re internally very bullish on the prospects of the drug, and the TAM is huge, approval this year, sales in 2026, they already have an approved drug in Libervant, etc. As someone with experience in the industry, it’s about 10x the play that CERO is, please, listen to reason and re-evaluate. If not into AQST, into almost anything else, please, I beg you.
I had one penny stock break out and wished I would have bet it all on AQST. But I just got into investing and didn’t have a grasp on how the stock market worked. It’s all about the quantity of shares that really makes the difference. I’ve had two penny stocks fail but it’s the ones that break out onto the exchange that makes that gamble pay off in the long run. Pick a young company you believe in and let it roll 😉. Oh and if I would have sunk $5K into AQST back when it was a dollar a share I could have cashed out $25K profit in less than 6 months but I’m in it for the long haul. Now I’m praying Lilium survives because if it does I will hit real pay dirt with them.
Alright, take a deep breath because this rant is way off the mark. Let’s actually break down the nonsense you just spewed about CABA and CAR-T therapies. First, the whole “CAR-T is cancerous and gives people secondary lymphomas” argument is just plain wrong. Yes, CAR-T comes with risks—cytokine storm, neurotoxicity, and other side effects—but calling it “cancerous” is just lazy fearmongering. Secondary malignancies happen, sure, but they’re rare and nowhere near the “majority” of cases. You’re throwing out buzzwords like ICANS without context, ignoring the fact that CAR-T has saved lives in patients who had zero other options. This isn’t speculation; it’s clinical data. Now, dragging ADAP and AUTL into this like they somehow predict CABA’s future is ridiculous. Biotech isn’t some one-size-fits-all game where every company in a space performs the same. ADAP and AUTL have different pipelines, different targets, and, frankly, different execution. CABA isn’t just a CAR-T oncology play—it’s breaking into autoimmune disease, a market that isn’t as crowded and has insane potential. Painting the whole CAR-T field as doomed because you didn’t like how a couple of other stocks performed is straight-up amateur hour. Then there’s your hype for AQST and APLS, which sounds more like someone desperate to pump their own positions than an actual argument. Sure, AQST’s dissolvable epi-strip is a neat innovation, but it’s not even in the same universe as CAR-T in terms of medical impact. And while APLS and SWTX are interesting plays, comparing them to a completely different kind of therapy is like comparing apples to oranges. Investing in biotech isn’t about picking your “favorite” product like it’s some popularity contest. You diversify across different approaches and markets to balance risk and reward. Acting like one class of therapy inherently trumps another just shows you don’t understand the space. And the “CAR-T isn’t worth it” take? Please. CAR-T therapies like Kymriah and Yescarta are already blockbusters that transformed cancer care. Yes, the field has challenges—manufacturing, costs, side effects—but it’s evolving fast. CABA isn’t even sticking to the same old CAR-T playbook. They’re pivoting to autoimmune diseases, which could completely change the game. Writing them off because you’re clinging to outdated critiques of first-gen CAR-T is ignorant at best. Look, biotech is risky. Everyone knows that. But trashing CABA with half-baked arguments and acting like AQST or APLS is some magical low-risk goldmine doesn’t make you sound smarter. It just shows you’re more interested in ranting than actually understanding the sector. TL;DR: If you’re gonna go off on a company, at least back it up with facts instead of hyperbole and bad comparisons. Dismissing CABA without acknowledging its innovative approach is a rookie move.
Jesus fucking christ boys, what is it with you fucks and clinically regarded plays. CAR-T therapies are fucking cancerous, literally, in that the majority of patients that take them get secondary lymphomas (as well as other nasty after effects like ICANS, cytokine storm and neurotoxicities in three quarters of patients). Look at how ADAP and AUTL have been trading lately. Look at how AUTL traded after its PDUFA approval earlier this month. For fuck sake, at least pick a decent ticker that has a remote prospect of working out. You have AQST that literally makes epi-pens as a fucking dissolvable strip that goes under the tongue instead of a fucking needle, with potentially billions in TAM, and you want to invest in third line cancer treatments that are _likely give you another form of cancer_ when taken. Or APLS with a literal wagon of GA and C3G patients to sell to. Or SWTX with Ogsiveo for desmoid tumors and a PDUFA at the end of February, two fucking blockbuster drugs ($1bn/year in sales) and a market cap of less than $3bn. Fucking get it together.
Boys, read my other comment in the thread, please. Crack it all on APLS, SWTX, PHAT, AQST, anything that actually has a shot of making shitloads of money, CAR-T companies have been tanking like fuck lately because they basically guarantee nasty after effects like secondary cancers, neurotoxicity, ICANS, etc. Market doubts they’ll amount to much more than third line treatments, why would you, as a patient, sign up for a therapy that has an 80% chance of giving you lymphoma unless it was your last roll of the dice?
I’d be cautious. ARS pharmaceuticals (SPRY) is already has a EpiPen replacement that is approved in Europe and further ahead in FDA approval schedule than this company. Also ARS has a cash war chest for marketing theirs. That said, I’m going to do DD into AQST as it is an interesting play (I have a anaphylactic allergy kid)
thanks for sharing, do you have a strong position in AQST?
If you know anything about Abigail Jenkins. Then you’d know not to invest a dime of your $$$ in AQST.
With stocks like AQST, it’s possible: https://preview.redd.it/xq7y05d9tyrd1.jpeg?width=1170&format=pjpg&auto=webp&s=092a6e2d2b5fc66fc462f95736e3ca1e9f20a982
AQST guys. Look at it
AQST if you want to ride a pharmaceuticals that will double in price by eoy.
I’m 1100 shares into AQST. Projected to hit 9-10$ by EOY. Strong buy rating. https://finance.yahoo.com/news/aquestive-therapeutics-comments-recent-fda-120000140.html
AQST will be the real winner
AQST has anaphylm a similar effect with a dissolvable film that is cheap. Can be kept in a wallet, purse or pocket. Size of a large postal stamp and just as effective as the current injection method. Will be on full market in 2025. I have 1000 shares @3.26
AQST guys. It’s going to $9-10 this quarter. Still under $4 today.
AQST for the long! Multiple approved drugs already so experience with FDA, 50mm in revenue, unique delivery method with film (think listerine strip but with meds), going after epi-pen with positive P3 results already and more in the pipeline. Pretty volatile so might be able to snag some in the low 3.xx to high 2.xx range over the next couple weeks/months. Thinkin it could 8-10x in a few years
AQST had a good er tonight with call in the morning and its cheap
Any other regards in AQST earnings tomorrow?
Any other regards playing the AQST and MPW ER this week? Both are hovering around the same value as before the market trumped its pants 👖
AQST ER this week. Check it out
Any other regards playing AQST or MPW earnings next week
No. I’m on the AQST cult
Still time to get in the AQST pump and dump before earnings in August
Buy MPW so I can exit at 6$ and have another 65k to buy more TSM. AQST also
Any other smooth brains playing AQST or MPW earnings. 1k shares @3.26 and 10k shares @4.76. Various calls on both. AQST has 100% buy rating but I have not been able to find out exactly why.
Anyone else playing $AQST earnings on 8/16? I have 3c,5c 8/16 and 5c 02/25/25 and 1000 shares.
AQST. Fun bags loading
AQST. Just launched the only oral treatment for cluster seizures in children (only competition is rectal), and can start selling to adults in 2017 when a competitors ODE runs out. Also in stage 3 trials for the first oral epinephrine (competitor to epi pen), with all results looking promising. NDA planned before end of year, and launch planned early next. There is a competitor who will launch first, but it is a nasal spray, whereas this can easily fit in your wallet. Near profitability already.
AQST here for the alternative to Epipen and similar products they are ramping up
“Most will go away in time”… sounds like people 🤣 You are correct - but like JFBR, GME, and KITT on Friday, wait for the spike in price and sell - can result in some quick profits for more investable assets. (which isn’t AQST!)
First taste of the big gains was AMC during the first short run - bought early and very low (mid-pandemic) sold off in chunks and got probably 500% or so net Current holdings: IRM 50% PLTR 48% AQST 28% GENI 27% HTGC 26% PG 10% The rest aren’t doing so hot, haha 🫣
Aqst boys..AQST. A real fucking company with real revenue with a real future and a real possibility, probability of a buyout